Literature DB >> 31626958

The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells.

Carolina Reduzzi1, Marta Vismara1, Lorenzo Gerratana2, Marco Silvestri1, Filippo De Braud3, Francesco Raspagliesi4, Elena Verzoni5, Serena Di Cosimo1, Laura D Locati5, Massimo Cristofanilli6, Maria Grazia Daidone1, Vera Cappelletti7.   

Abstract

The presence in the blood of patients with solid tumors of circulating cells expressing both epithelial and leukocyte markers (dual-positive cells, DPcells), has often been reported, though it has never been investigated in detail. A recent study suggested that DPcells are hybrid cells derived from the fusion of tumor cells with macrophages. Such fusion hybrids acquire macrophage-associated features endowing them with accelerated growth, increased motility, enhanced invasion activity and thus, a higher efficiency in metastasis formation. However, no direct evidence proving the tumor origin of circulating DPcells was provided in patients. Here we contribute a review of literature data on DPcells and on the hybrid theory with the aim of putting the current evidence both in a biological and clinical perspective and to generate new hypotheses on the mechanisms underlying tumor progression. To add further biological and clinical context to our literature review, we also report some preliminary data from our laboratory on the identification of DPcells in several solid tumors and confirmation of their malignant genotype, thus classifying them as DP-CTCs.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Circulating tumor cells (CTC); Dual positive circulating cells; Fusion-cells; Metastasis; The hybrid theory

Mesh:

Substances:

Year:  2019        PMID: 31626958     DOI: 10.1016/j.semcancer.2019.10.008

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  13 in total

Review 1.  Cell Lines of Circulating Tumor Cells: What Is Known and What Needs to Be Resolved.

Authors:  Yutaka Shimada; Tetsuo Sudo; Shusuke Akamatsu; Takuro Sunada; Akira Myomoto; Kiyoshi Okano; Kazuharu Shimizu
Journal:  J Pers Med       Date:  2022-04-21

Review 2.  Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer.

Authors:  Marilyne Labrie; Joan S Brugge; Gordon B Mills; Ioannis K Zervantonakis
Journal:  Nat Rev Cancer       Date:  2022-03-09       Impact factor: 69.800

3.  Characterization of a novel microfluidic platform for the isolation of rare single cells to enable CTC analysis from head and neck squamous cell carcinoma patients.

Authors:  Janis Stiefel; Christian Freese; Ashwin Sriram; Sabine Alebrand; Nalini Srinivas; Christoph Sproll; Madita Wandrey; Désirée Gül; Jan Hagemann; Jürgen C Becker; Michael Baßler
Journal:  Eng Life Sci       Date:  2022-04-06       Impact factor: 3.405

4.  Single-Cell Molecular Characterization to Partition the Human Glioblastoma Tumor Microenvironment Genetic Background.

Authors:  Francesca Lessi; Sara Franceschi; Mariangela Morelli; Michele Menicagli; Francesco Pasqualetti; Orazio Santonocito; Carlo Gambacciani; Francesco Pieri; Filippo Aquila; Paolo Aretini; Chiara Maria Mazzanti
Journal:  Cells       Date:  2022-03-26       Impact factor: 6.600

5.  Inflammation-Based Scores Increase the Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer.

Authors:  Svetlana Miklikova; Gabriel Minarik; Tatiana Sedlackova; Jana Plava; Marina Cihova; Silvia Jurisova; Katarina Kalavska; Marian Karaba; Juraj Benca; Bozena Smolkova; Michal Mego
Journal:  Cancers (Basel)       Date:  2020-05-01       Impact factor: 6.639

Review 6.  Hybrid/Atypical Forms of Circulating Tumor Cells: Current State of the Art.

Authors:  Evgeniya V Kaigorodova; Alexey V Kozik; Ivan S Zavaruev; Maxim Yu Grishchenko
Journal:  Biochemistry (Mosc)       Date:  2022-04       Impact factor: 2.487

7.  Transcriptional profiling of single tumour cells from pleural effusions reveals heterogeneity of epithelial to mesenchymal transition and extra-cellular matrix marker expression.

Authors:  Moen Sen; Ryan M Hausler; Keely Dulmage; Taylor A Black; William Murphy; Charles H Pletcher; Ling Wang; Chang Chen; Stephanie S Yee; Scott J Bornheimer; Kara N Maxwell; Ben Z Stanger; Jonni S Moore; Jeffrey C Thompson; Erica L Carpenter
Journal:  Clin Transl Med       Date:  2022-07

8.  Short-Term Ex Vivo Culture of CTCs from Advance Breast Cancer Patients: Clinical Implications.

Authors:  Nuria Carmona-Ule; Miriam González-Conde; Carmen Abuín; Juan F Cueva; Patricia Palacios; Rafael López-López; Clotilde Costa; Ana Belén Dávila-Ibáñez
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

9.  Antigen-agnostic microfluidics-based circulating tumor cell enrichment and downstream molecular characterization.

Authors:  Evan N Cohen; Gitanjali Jayachandran; Max R Hardy; Ananya M Venkata Subramanian; Xiangtian Meng; James M Reuben
Journal:  PLoS One       Date:  2020-10-23       Impact factor: 3.240

10.  Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients.

Authors:  Sarah Owen; Emily Prantzalos; Valerie Gunchick; Vaibhav Sahai; Sunitha Nagrath
Journal:  Biomedicines       Date:  2022-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.